Use of diuretics and other antihypertensive medications in relation to the risk of renal cell cancer

American Journal of Epidemiology

Volumn 140, Issue 9, 1994, Pages 792-804

  Weinmann, Sheila ^a   Glass, Andrew G ^b   Weiss, Noel S ^c   Psaty, Bruce M ^a,c   Siscovick, David S ^a,c   White, Emily ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CENTER FOR HEALTH RESEARCH   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antihypertensive agents; Diuretics; Hypertension; Kidney neoplasms

Indexed keywords

ANTIHYPERTENSIVE AGENT; CHLORTALIDONE; LOOP DIURETIC AGENT; POTASSIUM SPARING DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; RISK ASSESSMENT;

AGED; ANTIHYPERTENSIVE AGENTS; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; DIURETICS; EPIDEMIOLOGIC METHODS; FEMALE; HUMAN; HYPERTENSION; KIDNEY NEOPLASMS; MALE; MIDDLE AGE; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028096923     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a117328     Document Type: Article

References (22)

1. Yu MC, Mach TM, Hanisch R, et al. Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma. J Natl Cancer Inst 1986;77:351-6.
2. McLaughlin JK, Blot WJ, Fraumeni JF. Diuretics and renal cell cancer. (Letter). J Natl Cancer Inst 1988;80:378.
3. Kreiger N, Marrett LD, Dodds L, et al. Risk factors for renal cell carcinoma: results of a population-based case-control study. Cancer Causes Control 1993;4:101-10.
4. McCredie M, Stewart JH. Risk factors for kidney cancer in New South Wales. II. Urological disease, hypertension, obesity and hormonal factors. Cancer Causes Control 1992;3:323-31.
5. Finkle WD, McLaughlin JK, Rasgon SA, et al. Increased risk of renal cell cancer among women using diuretics in the United States. Cancer Causes Control 1993;4:555-8.
6. Mellemgaard A, Moller H, Olsen JH. Diuretics may increase risk of renal cell carcinoma. Cancer Causes Control 1992;3:309-12.
7. Grove JS, Nomura A, Severson RK, et al. The association of blood pressure with cancer incidence in a prospective study. Am J Epidemiol 1991;134:942-7.
8. Fraser GE, Phillips RL, Beeson WL. Hypertension, antihypertensive medication and risk of renal carcinoma in California Seventh-Day Adventists. Int J Epidemiol 1990;19:832-8.
9. Asal NR, Geyer JR, Risser DR, et al. Risk factors in renal cell carcinoma. II. Medical history, occupation, multivariate analysis, and conclusions. Cancer Detect Prev 1988;13:263-79.
10. McCredie M, Ford JM, Stewart JH. Risk factors for cancer of the renal parenchyma. Int J Cancer 1988;42:13-16.
11. Department of Drugs, Division of Drugs and Toxicology, American Medical Association. Drug evaluations annual. Milwaukee, WI: American Medical Association, 1991.
12. National Toxicology Program. Toxicology and carcinogenesis studies of furosemide in F344/N rats and B6C3F mice. Research Triangle Park, NC: National Institute of Environmental Health Sciences, 1989. (NTP Technical Report no. 356).
13. Lijinsky W, Reuber MD. Pathologic effects of chronic administration of hydrochlorothiazide, with and without sodium nitrate, to F344 rats. Toxicol Ind Health 1987;3:413-22.
14. 3 cotransport in rat renal cortex. (Abstract). Clin Res 1989;37:585A.
15. Walsh-Reitz MM, Toback FG. Kidney epithelial cell growth is stimulated by lowering extracellu-lar potassium concentration. Am J Physiol 1983; 244:C429-32.
16. Alpem RJ, Toto RD. Hypokalemic nephropathy—a clue to cystogenesis? (Editorial). N Engl J Med 1990;322:398-9.
17. Riemenschneider T, Bohle A. Morphologic aspects of low-potassium and low-sodium nephropathy. Clin Nephrol 1983;19:271-9.
18. Jackson CD, Fishbein L. A toxicological review of beta-adrenergic blockers. Fundam Appl Toxicol 1986;6:395-422.
19. National Toxicology Program. Toxicity and carcinogenesis studies of alpha-methyldopa ses-quihydrate in F344/N rats and B6C3F1 mice. Research Triangle Park, NC: National Institute of Environmental Health Sciences, 1989. (NTP Technical Report no. 348).
20. National Cancer Institute. Bioassay of reserpine for possible carcinogenicity. Bethesda, MD: National Cancer Institute, 1980. (National Cancer Institute Carcinogenesis Technical Report Series 193).
21. Ioannides C, Okine L, Parke DV. Effects of beta-adrenoceptor antagonists on the hepatic mixed-function oxygenases in the rat. Br J Pharmacol 1979;67:451P-2P.
22. Hiatt RA, Tolan K, Quesenberry CP. Renal cell carcinoma and thiazide use: a historical case-control study (California, USA). Cancer Causes Control 1994;5:319-25.